In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
about
Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapyWhat lessons can be learned from γδ T cell-based cancer immunotherapy trials?γδ T Cell Immunotherapy-A ReviewAdoptive cell therapy for sarcomaγδ T cells for cancer immunotherapy: A systematic review of clinical trialsHarnessing the power of Vδ2 cells in cancer immunotherapyγδ T Cells in HIV Disease: Past, Present, and FutureAnti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.A Novel Prothrombotic Pathway in Systemic Sclerosis Patients: Possible Role of Bisphosphonate-Activated γδ T Cells.Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates.Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas.Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity.Anti-tumour activity of bisphosphonates in preclinical models of breast cancer.Plasticity of γδ T Cells: Impact on the Anti-Tumor ResponseClinical applications of gamma delta T cells with multivalent immunity.A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.Breast cancer at bone metastatic sites: recent discoveries and treatment targets.Regulation of development of CD56 bright CD11c + NK-like cells with helper function by IL-18.Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?Impact of persistent HIV replication on CD4 negative Vγ2Vδ2 T cells.Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism.Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome.Azathioprine therapy selectively ablates human Vδ2⁺ T cells in Crohn's disease.Hyperactivation and in situ recruitment of inflammatory Vδ2 T cells contributes to disease pathogenesis in systemic lupus erythematosus.Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?The anti-tumour effects of zoledronic acidEffective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells.Effect of zoledronate on the responses of osteocytes to acute parathyroid hormone.Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.The invisible arm of immunity in common cancer chemoprevention agents.In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals.γδ T cells and their potential for immunotherapy.Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulationA phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.Combination strategies to enhance antitumor ADCC.
P2860
Q26781175-D2C42741-0EBD-4261-BFFF-BBEDF744E4C0Q26849323-807C35FB-282E-45FF-B5E2-68CC4458ED0CQ26995102-A3DCEDE4-E7ED-480D-BAF0-A3822D9BBAD5Q27009541-47218012-0077-44B7-A677-2C7515E74816Q27021705-1C843D57-0244-495A-A57B-DCCF31BBA332Q27027547-DAEFE11D-9EA8-4316-BB03-BBD9C2029C34Q28084822-E5299687-042D-494A-A205-F0EE533828BCQ33920919-82A72D6D-D3EC-4247-B605-34FFD690C40AQ34148693-FDDC68BE-7F64-42B1-A43C-F2A3011FA5F5Q34230320-1E17DA58-BD8C-439D-80F8-4665E52DDC09Q34493921-41785825-8EA5-4E9D-9796-22EFC1041923Q34560345-0DFAB2A7-E21D-4744-92D2-B32CF7C1104AQ34613492-71F8957A-B23E-4E99-B878-2F7C6BFB5F72Q34652408-63BE0889-6F77-4E97-B658-9F024A72C3C9Q34677859-8300DA29-1251-4788-927A-D0B00A2551BDQ34743969-24AD2F82-92BA-4676-B85B-440CAE8B2B95Q34939979-1DE7AD59-684D-4C0C-9701-832D1B3C8635Q35077632-5EB06788-AAFF-492F-8666-14DFA1F40FA9Q35226178-1279273C-0B53-4ADC-918F-D2BCDB6578C9Q35799192-4421BA17-8F2A-4C1E-BA38-A8AFA3BF84E7Q35883452-BBBF6DA1-70C3-483F-BC21-696C6AAD17CDQ35889808-E00DD00E-2944-4C3B-8D37-9ED46A295031Q35935862-69E60C8F-CEA7-418E-831C-AD00680976C8Q36040498-498266C1-00D7-4F95-9C14-A0A01F982664Q36099417-A42E13D0-4196-44E1-8935-A88A70A6662CQ36491357-F9B90FDC-24EC-47FF-B7FB-A99B27257AAFQ36491653-D1A505FC-EFC6-4417-BB83-6DCDCEC42EE6Q36597374-8F6E60D9-F463-4F09-80A9-052768312B80Q36653524-86C14073-16B2-4F70-B00F-A3332DC5555FQ36803818-44148A37-3DCC-480A-A5EF-99E63840471CQ36849984-8133A578-CCF1-4A31-8258-32B8A655B362Q37127038-941C2F5B-32CB-4916-942F-EF8EB6885521Q37172099-59C16C7D-580C-4895-AA1A-937E9207EAB1Q37354985-BD896A08-5AAF-4F90-9923-419E8D92AF2AQ37515155-53388786-4ADE-471E-9F4C-1CB390EE962DQ37576001-53F4B515-2B60-47C0-AD79-2DE4EF0D3E7CQ37655345-22257AE7-FA09-4CBF-907E-71FFFB12909FQ37656386-07DD2016-B8B3-4572-88EC-87F070967711Q37729133-5A1DC6DC-AD50-40DF-947F-90756F37411AQ38014085-26C2044D-56D6-40CB-B4F5-F1FAD973DB7B
P2860
In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
In vivo manipulation of Vgamma ...... vanced breast cancer patients.
@en
In vivo manipulation of Vgamma ...... vanced breast cancer patients.
@nl
type
label
In vivo manipulation of Vgamma ...... vanced breast cancer patients.
@en
In vivo manipulation of Vgamma ...... vanced breast cancer patients.
@nl
prefLabel
In vivo manipulation of Vgamma ...... vanced breast cancer patients.
@en
In vivo manipulation of Vgamma ...... vanced breast cancer patients.
@nl
P2093
P2860
P50
P1476
In vivo manipulation of Vgamma ...... vanced breast cancer patients.
@en
P2093
A C Hayday
C La Mendola
S Buccheri
P2860
P304
P356
10.1111/J.1365-2249.2010.04167.X
P577
2010-05-10T00:00:00Z